View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/SAMHSA | RIN: 0930-AA22 | Publication ID: Fall 2016 |
Title: Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements | |
Abstract:
On July 8, 2016, SAMHSA finalized a rule to increase access to buprenorphine and the combination buprenorphine/naloxone (Medication Assisted Treatment for Opioid Use Disorders). Concurrently with this final rule, SAMHSA issued a Supplemental Notice of Proposed Rulemaking seeking further comment on reporting provisions that would apply to physicians prescribing buprenorphine for up to 275 patients.
|
|
Agency: Department of Health and Human Services(HHS) | Priority: Economically Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: Yes | Unfunded Mandates: No |
CFR Citation: 42 CFR 8 | |
Legal Authority: 21 U.S.C. 823(g)(2) |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: Federal, Local, State, Tribal |
Federalism: No | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Brian Altman Legislative Director Department of Health and Human Services Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Rockville, MD 02857 Phone:240 276-2009 Email: brian.altman@samhsa.gov |